Skip to content
The Spore PatchPublishing · Evidence · Conservation

Atlas chapter 23 · Skin / hydration

Enoki / Enokitake

Flammulina filiformis (trial-reported identity: Flammulina velutipes)

E3+ narrow+ — Supports the tested propositionR1
Proposition / claim
Improved cheek hydration over four weeks from the tested dried-powder product
Evidence owner
Cultivar Oki-Shirayuki 919, as a tested dried-powder product
Dominant uncertainty
Independent hydration replication
Organism
Enoki / Enokitake
Tested intervention
Food product containing 3 g/day dried Enoki powder from cultivar Oki-Shirayuki 919.
Evidence target
Standardized preparation
Intervention description
Daily food product containing 3 g dried powder of Enoki cultivar Oki-Shirayuki 919 for four weeks. Trial-reported organism identity: Flammulina velutipes. Modern taxonomic context: cultivated East Asian Enoki is generally assigned to Flammulina filiformis. The published trial identity and the modern taxonomic context are preserved separately.
Population
30 healthy adults aged 20-59 years who completed the four-week trial; 15 intervention and 15 placebo.
Comparator
Placebo. Randomized, double-blind, placebo-controlled trial.
Outcome
Cheek-skin hydration increased significantly more in the Oki-Shirayuki 919 intervention group than placebo over four weeks (p = .033; treatment-versus-placebo change). Related neutral endpoint: the treatment-versus-placebo change in transepidermal water loss (TEWL) was not statistically significant (p = .104). Hydration and TEWL are reported separately and are not collapsed into a single skin-health endpoint; no skin-barrier, wrinkle, anti-ageing, rejuvenation or disease-treatment effect is claimed.
Evidence maturity (E)
E3+ narrow
Direction
+ — Supports the tested proposition
Historical flag (H)
Not specified at dossier level
Replication (R)
R1
Claim Gap (CG)
CG1 for cultivar-specific hydration wording
Evidence Transfer Vector
I / T / O / D / R, for the expanded claim "Enoki supplements reverse skin ageing." I: Oki-Shirayuki 919 tested food preparation -> arbitrary Enoki supplement. T: trial cultivar -> broad species/category. O: hydration -> skin ageing. D: four weeks -> chronic anti-ageing effect. R: one 30-person trial -> clinically proven.
Taxonomic Transfer Confidence
East Asian cultivated 'F. velutipes' → F. filiformis: HIGH contextually. Cultivar-specific molecular authentication not located during this audit.
Intervention Transfer Confidence
Oki-Shirayuki 919 → generic Enoki: LOW-MODERATE
Safety
S1
Conservation
C0/C+
Resolution zone
RZ-2
Next best experiment
Larger independent cultivar-specific hydration RCT with TEWL retained
Primary references
  1. Nagae M, Isa A, Ishikawa S, Muta S, Shimizu K. Effect of Oral Intake of Flammulina velutipes (Enokitake) on Skin Condition in Healthy Adult Women: A Randomized, Double-Blind, Placebo-Controlled Study on Mental and Physical Health. Cosmetics. 2023;10(2):57. DOI: 10.3390/cosmetics10020057
  2. Wang PM, Liu XB, Dai YC, Horak E, Steffen K, Yang ZL. Phylogeny and species delimitation of Flammulina: taxonomic status of winter mushroom in East Asia and a new European species identified using an integrated approach. Mycological Progress. 2018;17(9):1013-1030. DOI: 10.1007/s11557-018-1409-2
  3. Liu F, Wang SH, Jia DH, Tan H, Wang B, Zhao RL. Development of Multiple Nucleotide Polymorphism Molecular Markers for Enoki Mushroom (Flammulina filiformis) Cultivars Identification. Journal of Fungi. 2023;9(3):330. DOI: 10.3390/jof9030330. PMID: 36983498. PMCID: PMC10056640
Source chapter
Chapter 23, The Fungal Evidence Atlas

Governing principle

Evidence belongs first to the intervention actually tested.

This record has been checked against its source chapter and approved for publication. That editorial check is separate from the strength of the evidence, which is shown by the grades above. How the grades work →

Evidence records are not medical advice. Findings are confined to the exact preparations and study conditions described. Speak to a qualified clinician before using any fungal product alongside treatment.